Tesamorelin Dosage: The Approved Regimen and What Trials Measured
Tesamorelin is unusual among peptides sold online: it is an actual approved medicine, with an actual label, for an actual indication. That makes the honest version of this page much shorter than the marketing version.
Tesamorelin is a prescription growth-hormone-releasing factor analogue approved in the United States to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. The pivotal trials used 2 mg once daily by subcutaneous injection; the later reformulated product is labelled at 1.4 mg once daily, and the two are not interchangeable milligram for milligram because the formulations differ. It is not approved for bodybuilding, general fat loss, anti-ageing or growth-hormone optimisation in healthy adults, and it has never been trialled for those uses. Anyone using tesamorelin should be doing so on a prescription, with IGF-1 and glucose monitoring.
Tesamorelin amounts as they appear in the approved labelling and pivotal trials
| Use case | Amount reported in sources | What to know |
|---|---|---|
| Pivotal phase III trials, HIV-associated lipodystrophy | 2 mg once daily, subcutaneous, abdominal injection | Two multicentre randomised placebo-controlled trials over 26 weeks, with a 26-week extension phase. Source |
| Reformulated approved product | 1.4 mg once daily, subcutaneous | A later formulation with different reconstitution and storage; check the specific product's label rather than assuming equivalence. Source |
| Route and site | Subcutaneous injection into the abdomen, rotating sites | Injection-site reactions are the most common adverse events in the trials; rotation is part of the labelled instructions. Source |
| Use in healthy adults for fat loss or anti-ageing | No studied dose | No trials exist in this population. Any amount used for these purposes is unstudied and off-label. Source |
Figures are amounts reported in the cited sources, not a personal recommendation. Your own amount depends on your health, medicines and blood work.
What tesamorelin is and what it was approved to do
Tesamorelin is a stabilised analogue of growth-hormone-releasing hormone. Rather than supplying growth hormone directly, it prompts the pituitary to release the body's own, which produces a pulsatile pattern closer to normal physiology than injected hGH. It received FDA approval in 2010 for a narrow indication: reduction of excess visceral abdominal fat in adults with HIV who have lipodystrophy.
That indication exists because a specific problem needed solving. Some people on long-term antiretroviral therapy accumulate deep abdominal fat that behaves metabolically badly and does not respond well to diet or exercise. Tesamorelin was developed and tested for that population and that fat compartment.
Everything else attached to the name — recomposition, anti-ageing, sleep quality, general fat loss in healthy people — sits outside the evidence base entirely. It is not that those uses failed in trials; they were never trialled.
- A GHRH analogue that stimulates the body's own growth hormone release
- Approved in 2010 for HIV-associated lipodystrophy
- Target was visceral, not subcutaneous, abdominal fat
- No trials in healthy adults for cosmetic or performance goals
What the pivotal trials measured
The two phase III trials randomised adults with HIV-associated abdominal fat accumulation to daily tesamorelin or placebo for 26 weeks, with a further 26-week phase. The primary endpoint was change in visceral adipose tissue measured by CT scan at the L4-L5 level — a direct anatomical measurement, not a proxy.
The trials reported a reduction in visceral adipose tissue in the treated group relative to placebo, with an accompanying rise in IGF-1 as expected from the mechanism. Effects on triglycerides were also reported. Importantly, the reduction reversed after treatment stopped, which is why the label frames it as ongoing therapy rather than a course.
Blood glucose behaviour is the recurring caution. Growth hormone reduces insulin sensitivity, and the trial data prompted labelling attention to glucose monitoring, particularly in people who already have impaired glucose tolerance or diabetes.
- Primary endpoint: visceral adipose tissue on CT at 26 weeks
- IGF-1 rose, consistent with the mechanism
- Benefit reversed after discontinuation
- Glucose tolerance can worsen — monitoring is part of the label
Why the two milligram figures both exist
The original approved product was dosed at 2 mg daily. A later reformulation was approved at 1.4 mg daily, along with changes to reconstitution volume and storage requirements. The lower number is not a dose reduction in the ordinary sense; it reflects a different formulation delivering comparable exposure.
This is a real trap when people copy numbers between sources. A protocol quoting 2 mg alongside a product labelled for 1.4 mg is mixing two products. The label that comes with the specific vial in hand is the only correct reference.
It also matters for compounded or grey-market material, where neither formulation applies and there is no assurance the vial contains what the label claims.
- Original product: 2 mg daily
- Reformulated product: 1.4 mg daily, different reconstitution and storage
- Numbers are not interchangeable between products
- Compounded or research-grade material has no verified strength at all
Monitoring, contraindications and who should not use it
Because tesamorelin works by raising growth hormone and therefore IGF-1, monitoring IGF-1 is standard, along with fasting glucose or HbA1c. The label contraindicates use in pregnancy, in active malignancy, and in people with disruption of the hypothalamic-pituitary axis from tumour, surgery, radiation or head trauma.
The malignancy contraindication follows directly from the mechanism: IGF-1 is a growth signal, and raising it deliberately in someone with an active or recent cancer is not a risk anyone has quantified.
Fluid retention, joint pain, muscle aches, paraesthesia and carpal-tunnel-type symptoms are recognised class effects of raising growth hormone and were reported in the trials. Hypersensitivity reactions have also been described.
- Monitor IGF-1 and glucose control
- Contraindicated in pregnancy and active malignancy
- Contraindicated with disrupted hypothalamic-pituitary axis
- Fluid retention, arthralgia and paraesthesia are recognised effects
What the published studies found
Each entry below links straight to the paper or the health authority page so you can read the original rather than take our word for it.
- Phase III trials of tesamorelin in HIV-associated lipodystrophy
Randomised, double-blind, placebo-controlled multicentre trials, 26 weeks + extension
Daily tesamorelin reduced visceral adipose tissue measured by CT compared with placebo, raised IGF-1, and the reduction reversed after treatment stopped.
- Approved product labelling
FDA-approved prescribing information
Labels the indication, the once-daily subcutaneous dose for the specific formulation, contraindications in pregnancy and active malignancy, and glucose monitoring requirements.
- Registered tesamorelin studies
Clinical trial registry search
Registered studies cluster around HIV-associated lipodystrophy and metabolic endpoints such as liver fat; there is no registered trial base for cosmetic or performance use in healthy adults.
Side effects reported in the literature
Commonly reported
- Injection-site redness, itching, pain or bruising
- Joint pain and muscle aches
- Swelling from fluid retention, including in hands and feet
- Numbness or tingling, including carpal-tunnel-type symptoms
- Nausea
Serious, seek medical advice
- Worsening glucose tolerance or new-onset diabetes
- Hypersensitivity reactions, including rash and urticaria
- Concerns relating to neoplasm growth — contraindicated in active malignancy
- Fluid retention severe enough to require discontinuation
Summarised from DailyMed — tesamorelin prescribing information. Report anything unexpected to your own doctor or pharmacist.
Interactions to check with a pharmacist
| Medicine or condition | What sources report |
|---|---|
| Insulin and other glucose-lowering medicines | Growth hormone reduces insulin sensitivity; glucose-lowering therapy may need review and closer monitoring. Source |
| Corticosteroids and cortisone-based therapy | Growth hormone alters cortisol metabolism, which can change the effective dose of replacement steroid therapy. Source |
| Drugs metabolised by cytochrome P450 | Growth hormone can alter CYP-mediated clearance, so narrow-therapeutic-index drugs deserve review. Source |
| Anti-doping programmes | Growth hormone releasing factors and their analogues are prohibited at all times under WADA S2. Source |
This is not a complete interaction list. Check your own medicines with a pharmacist before combining anything.
This page is reference material, not medical advice. Supplements interact with prescription medicines and with each other. Talk to a doctor or pharmacist before starting anything, especially if you are pregnant, breastfeeding, managing a health condition or taking prescription medicine.
Frequently asked questions
What is the approved tesamorelin dose?
The pivotal trials used 2 mg once daily by subcutaneous injection into the abdomen. A later reformulated product is labelled at 1.4 mg once daily. Because the formulations differ, the two figures are not interchangeable and the label supplied with the product is the correct reference.
What is tesamorelin approved for?
In the United States it is approved to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. That is the only approved indication.
Does tesamorelin cause general weight loss?
The trials measured visceral abdominal fat on CT rather than body weight, and the target population was people with HIV-associated fat accumulation. There is no trial evidence for weight loss in healthy adults, and the visceral fat reduction reversed after treatment stopped.
Is tesamorelin the same as growth hormone?
No. It is a growth-hormone-releasing hormone analogue, so it stimulates the pituitary to release the body's own growth hormone in a pulsatile pattern, rather than delivering growth hormone directly.
Who should not take tesamorelin?
The label contraindicates it in pregnancy, in active malignancy, and in people with disruption of the hypothalamic-pituitary axis from a tumour, surgery, radiation or head trauma. It also requires care in anyone with impaired glucose tolerance or diabetes.
What monitoring does tesamorelin require?
IGF-1 and glucose control are the standard checks, because the mechanism raises IGF-1 and growth hormone reduces insulin sensitivity. This is one reason it is a prescription medicine rather than something to self-manage.
Is tesamorelin banned in sport?
Yes. Growth hormone releasing factors, including GHRH analogues, are prohibited at all times under WADA category S2.
Keep reading
Sources
Track your dose in DoseRoutine
Log what you actually take, get reminders at the right time and check interactions against everything else in your stack.
Sign up free →